Advancing in the involvement of FAK in drug resistance, Kang et al. reported that FAK promotes AKT-mediated YB-1 phosphorylation and CD44 expression to induce paclitaxel resistance in ovarian cancer cells, since FAK inhibition renders ovarian cancer cells sensitive to paclitaxel treatment [195]. Here, AKT1 is linked to ovarian carcinoma.